Replies to post #99484 on Biotech Values

[alertmeipp]

Teva may actually be a good stock to short.

[MotionMan]

MNTA: So the game has started and we are in the bottom half of the first inning. We just hit a grandslam in the top of the first to make it 4-0.
I think for new investors, any way you slice it, MNTA sub $20 makes for an attractive price point to enter the stock.
I expect the analysts to rachet up their price targets when they take a step back and realize the potential.

4 Billion dollars, 2.5 Billion in the U.S with the sole generic for the time being, waiting on Copaxone and M118 partnership. I can't see MNTA dipping below $16.

3 weeks ago we were at $15.28. Now the cloud has been lifted.